Stroke Research Today is a free monthly online journal that collates and summarizes the latest research about Stroke, including details on treatment, recovery, rehabilitation, signs, symptoms.

Endothelial progenitor cell research in stroke: a potential shift in pathophysiological and therapeutical concepts.

Rouhl RP, van Oostenbrugge RJ, Damoiseaux J, Cohen Tervaert JW, Lodder J

Department of Neurology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands. R.Rouhl@neurologie.azm.nl

BACKGROUND AND PURPOSE: Stroke is the leading cause of disability in the Western world; however, few therapies are at hand to decrease this burden. SUMMARY OF REVIEW: Endothelial progenitor cells (EPCs) have been introduced in cardiovascular medicine as factotums. EPCs can repair damaged endothelium and attenuate the development and progression of atherosclerosis. Also, EPCs can form new vessels in ischemic areas and thus promote recovery after ischemic events. In stroke, however, EPC research is limited. In our overview, we provide background information on EPC use as a risk marker and as a potential therapeutic agent. CONCLUSIONS: In our opinion, the lack of EPC studies in stroke should instigate vascular neurologists to participate in EPC research, as EPCs could also change pathophysiological concepts and improve clinical treatments in vascular neurology.

Published 24 June 2008 in Stroke, 39(7): 2158-65.
Full-text of this article is available online (may require subscription).

© 2004-2008 Stroke Research Today. All Rights Reserved.